Questcor Pharmaceuticals Q4 Profit Soars 53% on Higher Acthar Sales

Questcor continues its streak of strong profit growth with a huge spike in Acthar sales, especially in its relatively new rheumatology segment.

Feb 25, 2014 at 6:08PM

Shares of mid-cap biopharma Questcor Pharmaceuticals (NASDAQ:QCOR) attempted to keep its rally alive by reporting impressive growth in its fourth-quarter results after the bell this evening.

For the quarter, Questcor -- whose lone FDA-approved products is Acthar Gel, a product with 19 current indications – delivered strong sales growth of 51% to $242.9 million which was almost entirely a result of improved Acthar sales. Questcor notes that 8,100 vials of Acthar were shipped during the fourth-quarter, a 28% improvement over the 6,330 that were shipped during the fourth-quarter last year.

Questcor's CEO Don Bailey specifically pointed out that new paid prescriptions "grew about 30%" from the year-ago quarter with rheumatology-related new paid prescriptions providing the biggest surge. Bailey also mentioned that rheumatology now accounts for close to 30% of Questcor's total business after only three quarters of educating rheumatologists on its drug.

Additional sales strength was witnessed from its nephrotic syndrome segment which delivered paid new prescription growth of 5% year-over-year, as well as its multiple sclerosis relapse segment which saw 9% year-over-year new paid prescription growth.

Profit for the quarter improved an equally impressive 53% to $1.67 per share from $1.09 in the fourth-quarter of 2012.

Questcor's release points out that it repurchased 960,000 shares of its common stock during the quarter at an average price of $55.26 per share, and that its board had declared a $0.30 quarterly dividend. Despite mentioning numerous other indications it may seek for Acthar, Questcor did not issue any forward guidance.

Questcor shares were down near $4 per share, or 5%, in after hours at the time of this writing.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool has no position in any companies mentioned in this article. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers